INTRODUCTION
Pancreatic cancer is the fourth leading cause for cancer-related death in the Western world (1) . As conventional cancer treatments have little impact on disease course, almost all patients having pancreatic cancer develop metastases and die. To date, only surgical resection (possible in about 10-20% of patients) can increase the 5-year survival rate from 3% to 20%; systemic chemotherapy and/or radiation may only allow a marginal increase in survival (2, 3) . Therefore, new therapies based on the molecular biology of pancreatic cancer are needed to improve overall survival of patients with this aggressive disease.
In human pancreatic cancer overexpression of receptor tyrosine kinases (RTKs) such as fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and vascular-endothelial growth factor receptor (VEGFR), as well as their corresponding ligands is a common event and is eventually associated with reduced patient survival (4) (5) (6) . In particular, members of fibroblast growth factor (FGF) family have been shown to contribute to tumor cell proliferation and resistance to chemotherapy in human pancreatic cancer cell lines (7, 8) . Furthermore, since the FGF family comprises 23 different ligands, other members such as FGF-7 have also been associated with an increase in tumor cell motility and enhancement of metastases (9) . Therefore, targeting FGFR might improve current therapy concepts for pancreatic cancer patients.
However, expression of FGFR/PDGFR/VEGFR is not limited to cancer cells. In fact, these receptor systems are crucial mediators of tumor angiogenesis which is among the hallmarks of cancer (10, 11) . With no doubt, vascular-endothelial growth factor-A (VEGF-A) is the major regulator in this complex process by direct effects on endothelial cells (ECs) (12) .
However, there is increasing evidence that crosstalk between VEGFs and FGFs plays an important role in the promotion of tumor angiogenesis by mutually regulating their expression (13) (14) (15) (16) . In addition, recruitment of pericytes (e.g. vascular smooth muscle cells, VSMC) by PDGF-B is essential for maintenance of tumor angiogenesis, and cooperation of FGF-2 with PDGF-B has been shown to promote angiogenesis and metastasis formation in murine cancer models (17) . Thus, targeting FGFR/PDGFR/VEGFR by a multiple receptor tyrosine kinase inhibitor (RTK) might be a promising approach for anti-angiogenic therapy concepts.
TKI258 (formerly CHIR258) (4-amino-5-fluor-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one) is an orally available ATP-competitive inhibitor with activity against class III, IV and V RTKs, including FGFR, PDGFR and VEGFR (18). The substance has shown its anti-tumoral activity in various preclinical models, including mammary tumors, multiple myeloma, and colon cancer models (19) (20) (21) . Due to its inhibitory effects on multiple tyrosine kinases, TKI258 is thought to act on tumor cells and endothelial cells as well as pericytes.
In the present study, we assessed the combined anti-angiogenic and antitumor activity of targeting FGFR/PDGFR/VEGFR with TKI258 in a pancreatic cancer model. In vitro, a substantial inhibition of motility and growth factor-induced signaling was observed.
Furthermore, we evaluated its effects on tumor growth and metastasis in experimental murine models of subcutaneous and orthotopic pancreatic cancer in vivo. Results provide evidence that combined inhibition of FGFR/PDGFR/VEGFR might be a novel strategy to improve the outcome of patients with pancreatic cancer.
Taeger, et al. and maintained in 5% CO 2 at 37°C as described (22) . Recombinant human VEGF-A, PDGF-B, FGF-1, FGF-2 and FGF-7 were purchased from R&D Systems (Wiesbaden, Germany).
The FGFR/PDGFR/VEGFR inhibitor TKI258 was kindly provided by Novartis Oncology (Basel, Switzerland) and dissolved in DMSO (in vitro) and water (in vivo), respectively (Fig.   1A ).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide assays.
To evaluate cytotoxic effects of NVP-TKI258 on tumor cells, HUVEC and VSMC, cells were seeded in 96-well plates (1×10 3 per well) and exposed to various concentrations of TKI258. Respective concentrations of DMSO were added to controls. We used the MTT assay to assess cell viability as described before (22) .
Migration Assays.
To determine the effect of TKI258 treatment on cell motility, migration assays were performed using modified Boyden chambers as previously described (22, 23 Taeger, et al. Page 6 through the filters were counted in four random fields and average numbers were calculated.
In VSMCs, PDGF-B (10 ng/ml) and FGF-2 (50 ng/ml) were used as chemoattractant whereas motility in ECs was assessed with FGF-2 (50 ng/ml) and VEGF-A (50 ng/ml).
Western Blot Analyses for Activated Signaling Pathways and Receptor Expression.
Experiments were performed at a cellular density of 60% to 70%. Unless otherwise indicated, cells were incubated with TKI258 (0.5 µmol/l) before stimulation with either VEGF-A (10 ng/ml), PDGF-B (10 ng/ml), FGF-1 (50 ng/ml) or FGF-2 (50 ng/ml). Wholecell lysates were prepared as described elsewhere (24 Taeger, et al. 
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Statistical Analysis.
Statistical analyses were done using SigmaStat (Version 3.0). Results of in vivo experiments were analyzed for significant outliers using the Grubb's test (www.graphpad.com). Tumor-associated variables of in vivo experiments were tested for statistical significance using the Mann-Whitney U test for nonparametric data or ANOVA followed by Tukey's multiple comparison test for more than 2 groups. Effects on survival were determined by Kaplan-Meier analyses. The two-sided Student's t test was applied for analysis of in vitro data. All results are expressed as the mean ± standard error of the mean (SEM). protein level (Fig. 1E) . We conclude from these data that blocking FGFR with TKI258 might improve therapy with Gemcitabine in pancreatic cancer.
Effect of TKI258 on cancer cell motility.
Signaling induced by FGF-1 is known to promote metastatic spread of cancer cells (27) .
Hence, we evaluated the effect of targeting FGFR on tumor cell motility using Boyden Chamber assays. Results showed that TKI258 impairs constitutive tumor cell motility after 24 and 48 hours (data not shown). In addition, FGF-1-induced tumor cell migration was significantly blocked by TKI258 (Fig. 1D) . Similar results were obtained for FGF-7-induction of tumor cell motility (data not shown). To further determine the impact of TKI258 on constitutive motility, N-Cadherin and E-Cadherin expression was determined in cancer cells.
Interestingly, treatment with the inhibitor led to a dose-dependent down-regulation of NCadherin, whereas E-Cadherin tended to be up-regulated (Fig. 1E) . Taken together, our results demonstrate that blockade of FGFR with TKI258 leads to significant reduction of cancer cell motility in vitro, which could play a part in potential anti-metastatic effects in vivo.
TKI258 impairs activation of endothelial cells.
Induction of angiogenesis is important for tumor growth and metastases formation. Within this complex process, activation and recruitment of endothelial cells and pericytes is known to be crucial (12) . Since TKI258 not only inhibits FGFR, but also VEGFR, we next assessed its Taeger, et al. Page 12 induced by stimulation with either VEGF-A or FGF-2. This induction can be significantly impaired by treatment with TKI258 ( Fig. 2C left and Fig. 2C right) . Moreover, since TKI258 exhibits effects on VEGFR/c-Raf and FGFR/c-Raf activation in endothelial cells, we sought to investigate whether this inhibitor might also modulate factors involved in resistance to anti-VEGF therapy and survival of ECs (28) . Therefore, RT-PCR was applied to determine expression of DLL4 and survivin in endothelial cells and a robust (> 50%) down-regulation was detected for both ( Fig. 2D left and Fig. 2D right) . In summary, treatment of endothelial cells with TKI258 impairs growth factor signaling leading to cell motility and shows promise to reduce endothelial factors involved in resistance to anti-VEGF therapy.
Impact of TKI258 on pericytes (vascular smooth muscle cells).
In addition to endothelial cells, pericytes are essential for development of tumor angiogenesis (29) . Therefore, we included investigation of TKI258's effects on this cell type into the study. Human vascular smooth muscle cells (VSMCs) were used as a source of pericytes. Using MTT assays, only minor inhibition of growth was found upon treatment for 72 hours, even when cells were stimulated with PDGF-B and FGF-2 (data not shown).
However, since both PDGF-B and FGF-2 are involved in VSMC recruitment, we next determined the effects of TKI258 on activation of signaling intermediates. Western blot analyses revealed an inhibition of PDGF-B-induced Akt and ERK phosphorylation, as well as a reduction in phosphorylated STAT3 (Fig. 3A) . In contrast, stimulation with FGF-2 had no effect on activation of either ERK or Akt in VSMC (Fig. 3B) . On a functional level, motility of VSMCs was significantly impaired upon treatment with TKI258, only when cells were stimulated with either PDGF-B or FGF-2 ( Fig. 3C left and 3C right) . In addition, expression of survivin mRNA was significantly reduced, similar to our findings in ECs (Fig. 3D left) . Taeger, et al. Page 13 reduction in FGF-2 mRNA levels upon treatment with TKI258 (Fig. 3D right) . We conclude from these experiments that TKI258 elicits effects on PDGF-B and FGF-2-induced pericyte recruitment. (Fig. 4A) . Although the lower dosing group also showed a reduced tumor weight, this did not reach statistical significance. Moreover, a dose-dependent reduction in both lymph node and liver metastases was found upon treatment with TKI258 (Tab. 1). In the higher dosing group, reduction of lymph node metastases was significant, whereas reduction of liver metastases was noted, but not significant. To estimate the effects of our treatment on tumor vascularisation, CD31 + vessel area was determined. Again, treatment with 30 mg/kg/d showed significant reduction in tumor vascularisation, whereas lower dosing with 15 mg/kg/d demonstrated no effect (Fig. 4B) . In contrast, tumor cell proliferation determined by BrdU staining was significantly reduced at both, 15 and 30 mg/kg/d (Fig. 4C) . To further exclude that anti-tumoral effects are cell line specific, a subcutaneous tumor model was used with HPAF-II cells. Consistent with our results from the orthotopic model, a significant inhibition of tumor growth was observed by treatment with TKI258 (30 mg/kg/d) (Fig. 4D) , which was also reflected by final tumor weight (data not shown). In summary, these experiments show a Taeger, et al. Page 15 FGFR3, EGFR, as well as reduced expression of Hsp90 and survivin in tumor tissue. In turn, TKI258-treated tumors showed an increase in PDGFRα expression (Fig. 5C) . However, an up-regulation of Tie2 (2-fold) (Fig. 5D) and PDGF-B (3-fold) 
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DISCUSSION
Human pancreatic cancer remains associated with a high mortality since most patients present in advanced stages of the disease. Therefore, novel approaches are needed to improve the prognosis for these patients. Within our current study, we assessed the effects of targeting FGFR/PDGFR/VEGFR by using a novel multityrosine kinase inhibitor (TKI258) in pancreatic cancer models. Our results show that inhibition of these RTKs impairs multiple signaling pathways in tumor cells, endothelial cells and pericytes. Furthermore, we found a dose-dependent inhibition of pancreatic cancer growth and metastasis formation in vivo. In addition, survival of mice with established orthotopic tumors was significantly improved.
Taken together, our results suggest that the combination of targeting FGFR, PDGFR and VEGFR might be a novel way to improve outcome of patients with pancreatic cancer.
Previous studies have shown the anti-tumoral activity of targeting multiple RTKs with TKI258 in a variety of tumor models (20, 21, 30) . However, these studies focused on the inhibitory capacity of TKI258 on activation of PDGFRβ and VEGFR2 (21, 30) . In contrast, a recent report by Dey and coworkers describes that inhibition of FGFR in a breast cancer model is a crucial step for TKI258's antitumoral activity (20) . In our model we confirmed the effects of TKI258 on FGF-1-induced phosphorylation of ERK in tumor cells. Moreover, FGF-1-induced motility of pancreatic cancer cells was significantly suppressed by FGFR blockade with TKI258. However, in contrast to Dey and coworkers, we found no phosphorylation of Akt upon stimulation with FGF-1, which might be due to the fact that pancreatic cancer cells rely on other mechanisms of Akt phosphorylation than breast cancer cells (20) . We can add from our experiments that a decrease in survivin expression may be a factor. This is of particular importance since survivin is expressed in pancreatic adenocarcinoma and has been associated with resistance to chemo-and radiotherapy (31, 32) . This observation is further underlined by the improvement of chemosensitivity to Gemcitabine in MiaPaCa2 cells. Taeger, et al. Page 17 Therefore, our data indicate that targeting FGFR with TKI258 in pancreatic cancer cells reduces invasive properties and improves sensitivity to Gemcitabine in pancreatic cancer cells.
FGF signaling is not only involved in motility and survival of tumor cells, it is a crucial component of tumor angiogenesis (10, 12) . In particular, VEGF-A and FGF-2 are known to be major mediators of endothelial cell recruitment in terms of proliferation, migration and survival (33) . Alireza and coworkers have described a mechanism of chemoresistance in endothelial cells mediated via FGF-2-induced activation of Raf-1 (34), prompting our investigation into the effects of TKI258 on VEGF-A-and FGF-2-induced signaling. We found an inhibition of multiple signaling pathways including ERK, FAK and c-Raf. On a functional level, TKI258 was able to reduce both VEGF-A and FGF-2-induced endothelial cell migration. Moreover, upon treatment with this multikinase RTK inhibitior, a significant reduction in DLL4 and survivin expression was detectable. This is of particular interest since DLL4 has been associated with resistance to anti-VEGF therapy in some tumor models (28, 35, 36) . In addition, pericytes (or VSMCs as representatives of pericytes) are essential components of tumor angiogenesis. In particular, Nissen and coworkers described a synergistic prometastatic and proangiogenic activity of PDGF-B and FGF2 (15) . Using TKI258 we found that activation of signaling intermediates Akt and ERK by PDGF-B was diminished. Furthermore, PDGF-B-and FGF2 -mediated motility of VSMCs was impaired. In view of these data, one might speculate that targeting FGFR, PDGFR and VEGFR by TKI258 might improve current anti-angiogenic therapy strategies in solid tumors.
We used an orthotopic tumor model to further evaluate our findings. The advantage of this model is the high metastatic potential combined with an appropriate microenvironment. As expected from our in vitro data, treatment with TKI258 led to a significant reduction in tumor growth in a dose-dependent manner. One might speculate that the improved inhibition at the higher dosing group (30 mg/kg/d) might be mediated via anti-angiogenic effects since CD31 + vessel area was only reduced in this group. However, the effective dose of TKI258 30 mg/kg/d is in the lower range compared to that described in former reports (20, 21, 30, 37 ). In this model we also found a significant inhibition of metastasis formation in the lymph nodes and a trend to fewer liver metastases. These results are consistent with our in vitro data showing inhibition of tumor cell motility. However, several studies before have evaluated the effects of PDGFR and/or VEGFR inhibition on metastasis in pancreatic cancer models (23, (38) (39) (40) . Although a strong inhibition of metastasis has been described by most of them, clinical studies did not confirm these findings (41-43). Nonetheless, in addition to targeting PDGFR/VEGFR, TKI258 elicits strong effects on FGFR which adds a novel important antitumoral effect to our potential treatment arsenal. Taeger, et al. Page 19 increased activity of EGFR and FGFR pathways is associated with resistance against VEGF inhibitors (44). Surprisingly, we detected a down-regulation of FGFR3 and EGFR expression in our experiments. One might speculate that this is based on the fact that TKI258 blocks FGFR and PDGFR in addition to VEGFR. In contrast, an up-regulation of PDGFRα in TKI258-treated tumors was detected which is of particular interest since PDGFRα is associated with tumor progression and metastasis in various cancer entities (45, 46). Moreover, PDGFRα is the main receptor for PDGF-C which in-turn has been reported to be up-regulated in tumor-associated fibroblasts that mediate resistance to anti-VEGF therapy (47). However, as mentioned above, dosing for TKI258 was chosen far below the maximum tolerated dose in our experiments which offers the possibility to combine the inhibitor with conventional chemotherapy to further improve effects on survival. Nevertheless, taken together, our results clearly indicate that inhibition of multiple RTKs by TKI258 has the potential to impair tumor growth even in advanced stages. 
TABLES
